New drug combo shows promise for Tough-to-Treat hodgkin lymphoma
NCT ID NCT02940301
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 27 times
Summary
This study tests a combination of two drugs, ibrutinib and nivolumab, in adults with classical Hodgkin lymphoma that has come back or not responded to prior therapy. The goal is to see if this combination can shrink or control the cancer. About 18 participants will receive both drugs, and researchers will measure how many achieve a complete remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Winship Cancer Center of Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.